Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Seite 2
Apellis abstracts regarding the safety and efficacy of pegcetacoplan and unmet need in GA include:
- A Phase 1b Multi-Center, Open Label, Single-Arm Safety Study of Intravitreal Pegcetacoplan Supporting the Phase 3 DERBY and OAKS Studies for Geographic Atrophy: A Solution to “Tarmac Delay" – Poster Abstract – May 1, 10:15 a.m. - 12:00 p.m. ET
- Safety of Intravitreal Pegcetacoplan in Patients with Neovascular Age-Related Macular Degeneration Receiving Anti-VEGF Therapy – Poster Abstract – May 3, 4:30 p.m. - 6:15 p.m. ET
- Evaluation of Geographic Atrophy Secondary to Age-Related Macular Degeneration in Clinical Practice: Analysis of the AAO IRIS Registry – Poster Abstract – May 4, 2:15 p.m. - 4:00 p.m. ET
- Ocular Distribution of Pegcetacoplan in Rabbits Following a Single Intravitreal Injection. – Poster Abstract – May 5, 9:00 - 10:45 a.m. ET
- Impact of Pegcetacoplan on Progression of Nascent Atrophy in Age-Related Macular Degeneration (AMD) – Paper Abstract – May 7, 4:15 p.m. - 5:45 p.m. ET
About OPTIMA
The Ophthalmic Image Analysis (OPTIMA) group at the Medical University of Vienna is a leading data analysis laboratory for retinal diseases. OPTIMA is a multidisciplinary group in retinology,
computer science, and medical physics that develops computerized analysis methods for ophthalmic images and aims to individualize and lower treatment needs for patients affected by retinal
diseases.
Lesen Sie auch
About Pegcetacoplan
Pegcetacoplan is an investigational, targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and
progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. Pegcetacoplan is being
evaluated in several clinical studies across hematology, ophthalmology, nephrology, and neurology. Marketing applications for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) are under
review by the U.S. Food and Drug Administration (FDA), which has granted the application Priority Review designation, and the European Medicines Agency (EMA). Pegcetacoplan was granted Fast
Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of geographic atrophy and received orphan drug designation for the treatment of C3G by the FDA and European
Medicines Agency. For additional information regarding pegcetacoplan clinical trials, visit https://apellis.com/our-science/clinical-trials.